International law firm McDermott Will & Schulte represented Deep Track Capital, a Connecticut-based investment firm focused exclusively on the life sciences industry, in its Series C Financing round for Hemab Therapeutics (Hemab), a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding, and thrombotic disorders.

The McDermott team was led by Michael Flynn and Saarah Woodby.

Read Hemab’s announcement here.

Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.